# OnCo record brca-associated-tnbc (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/brca-associated-tnbc/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "brca-associated-tnbc" ;
  schema:name "BRCA-associated triple-negative breast cancer"@en ;
  schema:alternateName "Germline BRCA1 triple-negative breast cancer"@en, "gBRCA TNBC"@en, "Hereditary triple-negative breast cancer"@en, "BRCA1-related basal-like breast cancer"@en ;
  schema:description "Some triple-negative breast cancers arise because a person was born with a faulty BRCA1 or BRCA2 gene. This group is diagnosed younger, is found by a blood test NICE recommends for all women under 50 with triple-negative disease, and has options of its own: platinum chemotherapy works well, a year of olaparib lowers relapse, and surgery decisions weigh the risk of a second cancer."@en ;
  schema:url <https://onco.cc/cancers/brca-associated-tnbc/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/BRCA_mutation> ;
  schema:citation <https://doi.org/10.1200/jco.2014.57.1414>, <https://doi.org/10.1007/s10549-014-2980-0>, <https://doi.org/10.1200/jco.2008.16.6231>, <https://doi.org/10.1158/1055-9965.epi-11-0775>, <https://doi.org/10.1016/s1470-2045(17)30891-4>, <https://doi.org/10.1200/jco.19.01907>, <https://doi.org/10.1200/jco.20.02151>, <https://doi.org/10.1158/1078-0432.ccr-15-1465>, <https://doi.org/10.1200/jco.2012.47.8313>, <https://www.nice.org.uk/guidance/ng101/chapter/Recommendations>, <https://www.nice.org.uk/guidance/cg164/chapter/Recommendations>, <https://www.nice.org.uk/guidance/ta886> ;
  onco:tag "breast", "tnbc", "subtype-page" ;
  onco:related <https://onco.cc/cancers/tnbc/>, <https://onco.cc/cancers/tnbc-early/>, <https://onco.cc/cancers/tnbc-metastatic/>, <https://onco.cc/cancers/tnbc-basal-like-1/>, <https://onco.cc/cancers/medullary-pattern-breast-carcinoma/> ;
  onco:technologies <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/brca/>, <https://onco.cc/targets/parp/> ;
  onco:drugs <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/drugs/carboplatin/> ;
  onco:pathways <https://onco.cc/pathways/ddr/> ;
  onco:terms <https://onco.cc/terms/germline-brca-testing-criteria-tnbc/>, <https://onco.cc/terms/hrd-in-breast-cancer/>, <https://onco.cc/terms/risk-reducing-surgery-brca-carriers/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/terms/basal-like/> ;
  onco:trials <https://onco.cc/trials/olympia/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/trials/embraca/> ;
  onco:standardOfCare <https://onco.cc/technologies/germline-testing/>, <https://onco.cc/terms/germline-brca-testing-criteria-tnbc/>, <https://onco.cc/terms/germline-vs-somatic/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/trials/olympia/>, <https://onco.cc/technologies/parp-inhibitor/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/olaparib/>, <https://onco.cc/drugs/talazoparib/>, <https://onco.cc/trials/olympiad/>, <https://onco.cc/trials/embraca/>, <https://onco.cc/technologies/platinum/>, <https://onco.cc/terms/mastectomy/>, <https://onco.cc/terms/risk-reducing-surgery-brca-carriers/> .